{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Cell+Cancer+of+Head+and+Neck+%28SCCHN%29&page=2",
    "query": {
      "condition": "Squamous Cell Cancer of Head and Neck (SCCHN)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Cell+Cancer+of+Head+and+Neck+%28SCCHN%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T12:22:09.830Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04588038",
      "title": "NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Recurrent Hypopharyngeal Squamous Cell Carcinoma",
        "Recurrent Laryngeal Squamous Cell Carcinoma",
        "Recurrent Oral Cavity Squamous Cell Carcinoma",
        "Recurrent Oropharyngeal Squamous Cell Carcinoma",
        "Resectable Oropharyngeal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Efineptakin alfa",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Hyunseok Kang, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2021-03-12",
      "completion_date": "2025-02-03",
      "has_results": false,
      "last_update_posted_date": "2025-02-14",
      "last_synced_at": "2026-06-10T12:22:09.830Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04588038"
    },
    {
      "nct_id": "NCT00216138",
      "title": "Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Premedication",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoosier Cancer Research Network",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2004-03",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2011-05-02",
      "last_synced_at": "2026-06-10T12:22:09.830Z",
      "location_count": 18,
      "location_summary": "Newark, Delaware • Chicago, Illinois • Elkhart, Indiana + 13 more",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Elkhart",
          "state": "Indiana"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00216138"
    },
    {
      "nct_id": "NCT03529422",
      "title": "Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Larynx",
        "Lip",
        "Oral Cancer",
        "Digestive Organs--Diseases"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Intensity Modulated Radiotherapy Treatments",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2019-10-07",
      "completion_date": "2026-05-06",
      "has_results": true,
      "last_update_posted_date": "2025-07-20",
      "last_synced_at": "2026-06-10T12:22:09.830Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Chapel Hill, North Carolina • Charleston, South Carolina",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03529422"
    },
    {
      "nct_id": "NCT01612351",
      "title": "Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Lapatinib",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Ipsilateral Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Bilateral Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Transoral Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2012-06",
      "completion_date": "2025-05-19",
      "has_results": true,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-06-10T12:22:09.830Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01612351"
    },
    {
      "nct_id": "NCT00402545",
      "title": "C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Neoplasms"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2007-01",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2009-11-02",
      "last_synced_at": "2026-06-10T12:22:09.830Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00402545"
    },
    {
      "nct_id": "NCT06771219",
      "title": "SLV-154 Treatment of Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Squamous Cell Cancer of Head and Neck (SCCHN)",
        "NSCLC",
        "SCLC",
        "Cervical Cancer Metastatic",
        "Breast Cancer Metastatic",
        "Endometrial Cancer",
        "Ovarian Cancer",
        "Urothelial Cancer",
        "Sarcoma",
        "Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "SLV-154",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Solve Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2025-05-14",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-06-10T12:22:09.830Z",
      "location_count": 9,
      "location_summary": "Newport Beach, California • St Louis, Missouri • East Brunswick, New Jersey + 5 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "East Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06771219"
    },
    {
      "nct_id": "NCT02644122",
      "title": "SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "SF1126",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ezra Cohen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2016-11",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2018-07-11",
      "last_synced_at": "2026-06-10T12:22:09.830Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02644122"
    },
    {
      "nct_id": "NCT00080028",
      "title": "Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Oropharynx Cancer",
        "Larynx Cancer",
        "Hypopharynx Cancer"
      ],
      "interventions": [
        {
          "name": "Motexafin Gadolinium Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmacyclics LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-05-08",
      "last_synced_at": "2026-06-10T12:22:09.830Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina • San Antonio, Texas",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00080028"
    },
    {
      "nct_id": "NCT04034225",
      "title": "Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "SNS-301",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sensei Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2019-11-11",
      "completion_date": "2021-06-28",
      "has_results": true,
      "last_update_posted_date": "2023-03-24",
      "last_synced_at": "2026-06-10T12:22:09.830Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Newark, Delaware • Washington D.C., District of Columbia + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04034225"
    },
    {
      "nct_id": "NCT00591149",
      "title": "Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Carcinoma, Squamous"
      ],
      "interventions": [
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2007-06",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2017-06-14",
      "last_synced_at": "2026-06-10T12:22:09.830Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00591149"
    }
  ]
}